Company registration number 03045864 (England and Wales)
THE LEPROSY MISSION SHOP LIMITED
FORMERLY KNOWN AS TLM TRADING LIMITED
ANNUAL REPORT AND FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025
THE LEPROSY MISSION SHOP LIMITED
COMPANY INFORMATION
Directors
Gordon Brown - Represents The Leprosy Mission Global Fellowship from 25 September 2025
Gareth Evans - Appointed 16 December 2025
Nicholas Green
Stuart Green - Chair
Esther Kwan
Karen Mitchell
Amanda Norman - Chief Executive Officer
Colin Osborne - Represented The Leprosy Mission Global Fellowship until 25 September 2025
Peter Waddup - Represents the UK Supporting Countries of The Leprosy Mission
Company number
03045864
Registered office
80 Windmill Road
Brentford
Middlesex
United Kingdom
TW8 0QH
Auditor
Azets Audit Services
Westpoint
Lynch Wood
Peterborough
Cambridgeshire
United Kingdom
PE2 6FZ
Bankers
Barclays Bank PLC
Peterborough Business Centre
PO Box 294
Peterborough
United Kingdom
PE1 1EZ
Pension Scheme Actuaries
Peter Shellswell
First Actuarial LLP
Network House
Basing View, Basingstoke
Hampshire
RG21 4HG
THE LEPROSY MISSION SHOP LIMITED
CONTENTS
Page
Chair's Report
1
Strategic report
2 - 4
Directors' report
5
Directors' responsibilities statement
6
Independent auditor's report
7 - 9
Profit and loss account
10
Statement of comprehensive income
11
Balance sheet
12
Statement of changes in equity
13
Statement of cash flows
14
Notes to the financial statements
15 - 25
THE LEPROSY MISSION SHOP LIMITED
CHAIR'S REPORT
FOR THE YEAR ENDED 31 DECEMBER 2025
- 1 -
Stuart Green
Chair
22 April 2026
THE LEPROSY MISSION SHOP LIMITED
STRATEGIC REPORT
FOR THE YEAR ENDED 31 DECEMBER 2025
- 2 -
Chief Executive's Report for and on behalf of the Board of Directors
30 years of trading for good
In 2025 The Leprosy Mission Shop celebrated thirty years of business.  The occasion was marked with a thanksgiving service to express our gratitude to God for his faithfulness and to recognise the generosity and commitment of our customers, partners and suppliers. The service was held in person with many others joining the live stream. The event included afternoon tea and was attended by Paul Bristow, Mayor of Peterborough and Sam Carling, MP for North West Cambridgeshire.
Money raised equivalent to funding a large Leprosy Mission hospital
In 2025 The Leprosy Mission Shop raised £604k for The Leprosy Mission. £414k was raised by the sale of alternative gifts, Gifts for Life, with monies restricted to fund items such as low-cost houses, wells, latrines, meals, medicine and surgery for people affected be leprosy.  A further £190k was raised in donations added to orders. Whilst the combined amount was 3% behind budget and 4% behind the exceptional performance in 2024 the total delivered by the Shop to The Leprosy Mission equates to the full running costs of one of The Leprosy Mission's larger hospitals in India. Over and above this amount £46k was raised in gift aid.
Sales performed 4% above 2024
The very late date of Easter in 2025 affected sales in Q1 but a strong performance in Q2 and into Autumn/Winter meant the year ended with a 4% increase on 2024 gross sales. Christmas cards, Christmas gifts, stationery and books continue to make up a large proportion of the revenue from product sales.  A new digital campaign for Black Friday contributed to the good end of year performance.
New systems built future resilience
A significant investment, in terms of staff time, was made in the business by the replatforming of the website from Magento to Shopify. This work was carried out in-house, releasing the business from future dependency on an external developer, saving costs and increasing agility. Shopify also brings new opportunities for the Shop and its customers such as being able to offer personalised gift cards with orders (already implemented), easier drop ship integrations and gift vouchers.  Staff took the opportunity of this change in systems to streamline several internal processes.  As a result, the business, including the Accounts Department, is no longer reliant on the third-party warehouse for sales data, as all orders are processed in Shopify.
One-off circumstances led to a manageable loss
Several unexpected minor events combined in 2025 to deliver an unplanned but manageable operating loss for the business of £58k. This was partly due to an unavoidable delay in the launch of the Shopify website; sales being slightly behind budget and cost of goods being above of budget, but in line with sales. The business also decided to spend more than budgeted on social advertising as this was showing a strong return on investment.
Bumper sales in January 2026
2026 has started well with one of the best-ever performances in January thanks to an enhanced direct mail flier and well-executed digital marketing. Revenue was double January 2025, with the strong performance having the added advantage of clearing over 100 lines of stock and reducing stock holding.
Performance against 2025 objectives
The following objectives were set for 2025:
1)   To maximise income from long loyal customers by including products they love in the range.
In the course of 2025, a number of more traditional products were re-introduced or refreshed for the benefit of long loyal customers.  New email journeys were built, triggered by Shopify, to prompt customers who had not bought recently.
2)   To nurture existing customers by continuing to refresh the product range and the development of a "We miss you" communication plan.
Several new email journeys were implemented including “we miss you” and abandoned basket, resulting in an upturn of orders in these instances.
THE LEPROSY MISSION SHOP LIMITED
STRATEGIC REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
- 3 -
3)   To recruit new customers who will bring in income and become supporters of The Leprosy Mission by continuing direct mail outreach and increasing digital advertising.
Direct mail acquisition was executed as planned but the results have started to decline in recent years and direct marketing as a channel will be less of a priority for acquisition in 2026, focusing instead on digital acquisition which has been performing well.
4)   To ensure superb customer service for all, including excellent service from Elovate, our third-party warehouse, and better customer journeys and messaging.
Concerns raised in 2024/5 about the performance and fit of Elovate as the third-party warehouse for The Leprosy Mission Shop have been largely settled, owing to a new CEO at Elovate and sustained effort and attention to detail from both parties.
Alongside the introduction of Shopify, we launched a new tool called Gorgias to assist with customer service. This has proved highly successful and, as a result, the majority of customer enquiries have been handled in-house rather than by our third-party website, improving customer experience and saving costs.
5)   To raise £625k in GFLs and donations.
Income from Gifts for Life remained strong (1% behind budget), but donations were 8% below budget.  This is due to various factors including the lack of emergency appeals and Aidmatch funding.  For 2026 we will assess whether we should move to Shopify Plus which would allow us to have some control over the checkout page to promote donations.
6)   To select from and tweak our existing product ranges to meet the changing needs of our three main trade customers.
Internal priorities from our three main trade customers have limited sales growth in this area.  Analysis is being done on how best to maximise any B2B opportunities whilst prioritising B2C sales.
7)   To maximise the opportunities of the Shopify website.
The move to Shopify was identified in 2024 as a key factor in the future profitability of the company, increasing agility and saving future costs.  This was built in-house, though a four-month delay in switching to the new system meant we did not experience the savings as early as we had hoped. However, as a result of the move to Shopify, internal systems have already been improved and the business is no longer reliant on its third-party warehouse for order and financial data. New opportunities for the business and its customers are being explored.
Vision and mission 2026
The Leprosy Mission Shop shares the vision of The Leprosy Mission Global Fellowship to defeat leprosy and transform lives.  The Shop is committed to playing its part in the new Global Fellowship Strategy 2025-2030 through its mission:
To transform the lives of people affected by leprosy by trading responsibly and in line with our Christian ethos, enabling us to:
• Raise the profile of The Leprosy Mission and recruit new supporters
• Raise money through the sale of products, Gifts for Life and donations.
Objectives for 2026
1) Recruit new customers
2) Ensure superb customer service
3) Raise £660k in Gifts for Life and donations
4) Conduct a thorough review of the trade business
5) Identify 3 or 4 digital enhancements that are now possible because of the Shopify platform.
30 years on from its formation as company, with an experienced staff team, a renewed positive relationship with the third-party warehouse and the new Shopify website, The Leprosy Mission Shop is in a strong position to fulfil its mission of transforming the lives of people affected by leprosy in 2026 and beyond.
THE LEPROSY MISSION SHOP LIMITED
STRATEGIC REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
- 4 -

On behalf of the board

Amanda Norman - Chief Executive Officer
Director
22 April 2026
THE LEPROSY MISSION SHOP LIMITED
DIRECTORS' REPORT
FOR THE YEAR ENDED 31 DECEMBER 2025
- 5 -

The directors present their annual report and financial statements for the year ended 31 December 2025.

 

The Leprosy Mission Shop Limited is a subsidiary of The Leprosy Mission International (TLMI). TLMI is the leading and coordinating body for The Leprosy Mission Global Fellowship, a federation operating in the name of the Leprosy Mission in 30 countries.

Principal activities

The company’s main activity is the enhancement of The Leprosy Mission’s profile by means of its e-commerce website, direct mail, and social media marketing. The company increases the number of supporters for The Leprosy Mission, provides funds through donations added to orders, and promotes the sale of Gifts for Life for projects funded by The Leprosy Mission. The company supports the purchase and resale of products made by people affected by leprosy and other disadvantaged groups in the developing world. During 2022 the company rebranded and started trading under the name “The Leprosy Mission Shop” in order to facilitate the aim of attracting new supporters to The Leprosy Mission, formally changing its name at Companies House in 2025.

 

Vision

Leprosy Defeated, Lives Transformed

 

Mission

To transform the lives of people affected by leprosy by trading responsibly and in line with our Christian ethos, enabling us to:

Directors

The directors who held office during the year and up to the date of signature of the financial statements were as follows:

Gordon Brown - Represents The Leprosy Mission Global Fellowship from 25 September 2025
Gareth Evans - Appointed 16 December 2025
Nicholas Green
Stuart Green - Chair
Esther Kwan
Itayi Mapuranga - Resigned 1 July 2025
Karen Mitchell
Amanda Norman - Chief Executive Officer
Colin Osborne - Represented The Leprosy Mission Global Fellowship until 25 September 2025
Peter Waddup - Represents the UK Supporting Countries of The Leprosy Mission
Statement of disclosure to auditor

So far as each person who was a director at the date of approving this report is aware, there is no relevant audit information of which the company’s auditor is unaware. Additionally, the directors individually have taken all the necessary steps that they ought to have taken as directors in order to make themselves aware of all relevant audit information and to establish that the company’s auditor is aware of that information.

On behalf of the board
Amanda Norman - Chief Executive Officer
Director
22 April 2026
THE LEPROSY MISSION SHOP LIMITED
DIRECTORS' RESPONSIBILITIES STATEMENT
FOR THE YEAR ENDED 31 DECEMBER 2025
- 6 -

The directors are responsible for preparing the annual report and the financial statements in accordance with applicable law and regulations.

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law, the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period.

In preparing these financial statements, the directors are required to:

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company’s transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

THE LEPROSY MISSION SHOP LIMITED
INDEPENDENT AUDITOR'S REPORT
TO THE MEMBERS OF THE LEPROSY MISSION SHOP LIMITED
- 7 -
Opinion

We have audited the financial statements of The Leprosy Mission Shop Limited (the 'company') for the year ended 31 December 2025 which comprise the profit and loss account, the statement of comprehensive income, the balance sheet, the statement of changes in equity, the statement of cash flows and notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

 

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

 

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

Other information

The other information comprises the information included in the annual report other than the financial statements and our auditor's report thereon. The directors are responsible for the other information contained within the annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

 

We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of our audit:

THE LEPROSY MISSION SHOP LIMITED
INDEPENDENT AUDITOR'S REPORT
TO THE MEMBERS OF THE LEPROSY MISSION SHOP LIMITED (CONTINUED)
- 8 -
Matters on which we are required to report by exception

In the light of the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified material misstatements in the strategic report or the directors' report.

 

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion:

Responsibilities of directors

As explained more fully in the directors' responsibilities statement, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error. In preparing the financial statements, the directors are responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

A further description of our responsibilities is available on the Financial Reporting Council’s website at: https://www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor's report.

THE LEPROSY MISSION SHOP LIMITED
INDEPENDENT AUDITOR'S REPORT
TO THE MEMBERS OF THE LEPROSY MISSION SHOP LIMITED (CONTINUED)
- 9 -

Extent to which the audit was considered capable of detecting irregularities, including fraud

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above and on the Financial Reporting Council’s website, to detect material misstatements in respect of irregularities, including fraud.

 

We obtain and update our understanding of the entity, its activities, its control environment, and likely future developments, including in relation to the legal and regulatory framework applicable and how the entity is complying with that framework.  Based on this understanding, we identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion.  This includes consideration of the risk of acts by the entity that were contrary to applicable laws and regulations, including fraud.

 

In response to the risk of irregularities and non-compliance with laws and regulations, including fraud, we designed procedures which included:

 

 

Because of the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation.  This risk increases the more that compliance with a law or regulation is removed from the events and transactions reflected in the financial statements, as we will be less likely to become aware of instances of non-compliance.  The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

Use of our report

This report is made solely to the company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members as a body, for our audit work, for this report, or for the opinions we have formed.

Tracey Richardson BSc (Hons) FCA (Senior Statutory Auditor)
For and on behalf of Azets Audit Services, Statutory Auditor
Chartered Accountants
Westpoint
Lynch Wood
Peterborough
Cambridgeshire
PE2 6FZ
24 April 2026
THE LEPROSY MISSION SHOP LIMITED
PROFIT AND LOSS ACCOUNT
FOR THE YEAR ENDED 31 DECEMBER 2025
- 10 -
2025
2024
Notes
£
£
Turnover
3
1,506,413
1,446,803
Cost of sales
(563,501)
(521,204)
Gross profit
942,912
925,599
Marketing and distribution costs
(766,255)
(727,554)
Administrative expenses
(499,446)
(517,958)
Other operating income
264,660
291,673
Operating loss
5
(58,129)
(28,240)
Interest receivable and similar income
4
14,793
15,526
Loss before taxation
(43,336)
(12,714)
Tax on loss
-
0
-
0
Loss for the financial year
(43,336)
(12,714)

The profit and loss account has been prepared on the basis that all operations are continuing operations.

THE LEPROSY MISSION SHOP LIMITED
STATEMENT OF COMPREHENSIVE INCOME
FOR THE YEAR ENDED 31 DECEMBER 2025
- 11 -
2025
2024
£
£
Loss for the year
(43,336)
(12,714)
Other comprehensive income
-
-
Total comprehensive income for the year
(43,336)
(12,714)
THE LEPROSY MISSION SHOP LIMITED
BALANCE SHEET
AS AT 31 DECEMBER 2025
31 December 2025
- 12 -
2025
2024
Notes
£
£
£
£
Fixed assets
Intangible assets
10
5,769
-
0
Tangible assets
11
2,866
846
8,635
846
Current assets
Stocks
12
205,479
138,392
Debtors
13
55,472
68,169
Cash at bank and in hand
637,855
934,623
898,806
1,141,184
Creditors: amounts falling due within one year
14
(253,598)
(444,851)
Net current assets
645,208
696,333
Net assets
653,843
697,179
Capital and reserves
Called up share capital
16
200,000
200,000
Profit and loss reserves
453,843
497,179
Total equity
653,843
697,179
The financial statements were approved by the board of directors and authorised for issue on 22 April 2026 and are signed on its behalf by:
Stuart Green - Chair
Amanda Norman - Chief Executive Officer
Director
Director
Company registration number 03045864 (England and Wales)
THE LEPROSY MISSION SHOP LIMITED
STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 DECEMBER 2025
- 13 -
Share capital
Profit and loss reserves
Total
Notes
£
£
£
Balance at 1 January 2024
200,000
511,840
711,840
Year ended 31 December 2024:
Loss and total comprehensive income for the year
-
(12,714)
(12,714)
Distributions to parent charity under gift aid
9
-
(1,947)
(1,947)
Balance at 31 December 2024
200,000
497,179
697,179
Year ended 31 December 2025:
Loss and total comprehensive income for the year
-
(43,336)
(43,336)
Balance at 31 December 2025
200,000
453,843
653,843
THE LEPROSY MISSION SHOP LIMITED
STATEMENT OF CASH FLOWS
FOR THE YEAR ENDED 31 DECEMBER 2025
- 14 -
2025
2024
Notes
£
£
£
£
Cash flows from operating activities
Cash absorbed by operations
19
(301,048)
(37,671)
Investing activities
Purchase of intangible assets
(7,348)
-
0
Purchase of tangible fixed assets
(3,165)
(870)
Interest received
14,793
15,526
Net cash generated from investing activities
4,280
14,656
Financing activities
Dividends and distributions paid
-
0
(1,947)
Net cash used in financing activities
-
(1,947)
Net decrease in cash and cash equivalents
(296,768)
(24,962)
Cash and cash equivalents at beginning of year
934,623
959,585
Cash and cash equivalents at end of year
637,855
934,623
THE LEPROSY MISSION SHOP LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025
- 15 -
1
Accounting policies
Company information

The Leprosy Mission Shop Limited is a private company limited by shares incorporated in England and Wales. The registered office is 80 Windmill Road, Brentford, Middlesex, United Kingdom, TW8 0QH.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2
Going concern

Atruet the time of approving the financial statements, the directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. Thus the directors continue to adopt the going concern basis of accounting in preparing the financial statements.

1.3
Turnover

Turnover represents the amounts receivable for goods sold during the year, exclusive of Value Added Tax. Sales of goods are recognised upon the dispatch of goods to the customers after any returns.

 

Donations and Gifts for Life donations

These are received on behalf of TLM Great Britain and TLM Northern Ireland and passed on and accounted for in the respective charity.

 

Income from advertising space in trading catalogues

Trading catalogues provide space for promotion of the Mission's work and enable sales of Gifts for Life (GFL) and donations. The advertising income represents the fee charged to supporting countries in the UK.

1.4
Intangible fixed assets other than goodwill

Intangible assets acquired separately from a business are recognised at cost and are subsequently measured at cost less accumulated amortisation and accumulated impairment losses.

 

Intangible assets acquired on business combinations are recognised separately from goodwill at the acquisition date where it is probable that the expected future economic benefits that are attributable to the asset will flow to the entity and the fair value of the asset can be measured reliably; the intangible asset arises from contractual or other legal rights; and the intangible asset is separable from the entity.

Amortisation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Website
3 years straight line
1.5
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

THE LEPROSY MISSION SHOP LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
1
Accounting policies
(Continued)
- 16 -

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Office and Computer Equipment
3 years straight line

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.6
Impairment of fixed assets

At each reporting period end date, the company reviews the carrying amounts of its tangible and intangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.

Recoverable amount is the higher of fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted.

 

If the recoverable amount of an asset (or cash-generating unit) is estimated to be less than its carrying amount, the carrying amount of the asset (or cash-generating unit) is reduced to its recoverable amount. An impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the impairment loss is treated as a revaluation decrease.

Recognised impairment losses are reversed if, and only if, the reasons for the impairment loss have ceased to apply. Where an impairment loss subsequently reverses, the carrying amount of the asset (or cash-generating unit) is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset (or cash-generating unit) in prior years. A reversal of an impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the reversal of the impairment loss is treated as a revaluation increase.

1.7
Stocks

Stocks consist of merchandise for resale by The Leprosy Mission Shop Limited and are valued at the lower of cost and net realisable value. Cost is determined principally on the first in first out basis. Net realisable value is the expected price at which stock can be realised.

At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.

1.8
Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

THE LEPROSY MISSION SHOP LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
1
Accounting policies
(Continued)
- 17 -
1.9
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

 

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

 

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Other financial assets

Other financial assets, including investments in equity instruments which are not subsidiaries, associates or joint ventures, are initially measured at fair value, which is normally the transaction price. Such assets are subsequently carried at fair value and the changes in fair value are recognised in profit or loss, except that investments in equity instruments that are not publicly traded and whose fair values cannot be measured reliably are measured at cost less impairment.

Impairment of financial assets

Financial assets, other than those held at fair value through profit and loss, are assessed for indicators of impairment at each reporting end date.

 

Financial assets are impaired where there is objective evidence that, as a result of one or more events that occurred after the initial recognition of the financial asset, the estimated future cash flows have been affected. If an asset is impaired, the impairment loss is the difference between the carrying amount and the present value of the estimated cash flows discounted at the asset’s original effective interest rate. The impairment loss is recognised in profit or loss.

 

If there is a decrease in the impairment loss arising from an event occurring after the impairment was recognised, the impairment is reversed. The reversal is such that the current carrying amount does not exceed what the carrying amount would have been, had the impairment not previously been recognised. The impairment reversal is recognised in profit or loss.

Derecognition of financial assets

Financial assets are derecognised only when the contractual rights to the cash flows from the asset expire or are settled, or when the company transfers the financial asset and substantially all the risks and rewards of ownership to another entity, or if some significant risks and rewards of ownership are retained but control of the asset has transferred to another party that is able to sell the asset in its entirety to an unrelated third party.

Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

THE LEPROSY MISSION SHOP LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
1
Accounting policies
(Continued)
- 18 -
Basic financial liabilities

Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

 

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

 

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

Other financial liabilities

Derivatives, including interest rate swaps and forward foreign exchange contracts, are not basic financial instruments. Derivatives are initially recognised at fair value on the date a derivative contract is entered into and are subsequently re-measured at their fair value. Changes in the fair value of derivatives are recognised in profit or loss in finance costs or finance income as appropriate, unless hedge accounting is applied and the hedge is a cash flow hedge.

 

Debt instruments that do not meet the conditions in FRS 102 paragraph 11.9 are subsequently measured at fair value through profit or loss. Debt instruments may be designated as being measured at fair value through profit or loss to eliminate or reduce an accounting mismatch or if the instruments are measured and their performance evaluated on a fair value basis in accordance with a documented risk management or investment strategy.

Derecognition of financial liabilities

Financial liabilities are derecognised when the company’s contractual obligations expire or are discharged or cancelled.

1.10
Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

1.11
Taxation

The Leprosy Mission Shop Limited is a wholly owned subsidiary of The Leprosy Mission International. The Leprosy Mission Shop Limited currently has brought forward tax losses which have been offset against any taxable profits of the company. It is the intention of the directors to donate an amount of profit to the parent charity under the Gift Aid scheme, subject to cashflow availability.

1.12
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

 

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

 

Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

THE LEPROSY MISSION SHOP LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
1
Accounting policies
(Continued)
- 19 -
1.13
Retirement benefits

The company operates a non-contributory defined contribution pension scheme with AVIVA (former Friends Life). Previously it participated in a multi-employer defined benefit scheme, providing benefits based upon career averaged revalued earnings which was closed on 31 March 2013 for all employees. In accordance with FRS102, deficit funding for the pension scheme in which the company participates is accrued at current value in creditors falling due after more than one year.

1.14
Leases

Rentals payable under operating leases, including any lease incentives received, are charged to profit or loss on a straight line basis over the term of the relevant lease except where another more systematic basis is more representative of the time pattern in which economic benefits from the leases asset are consumed.

2
Judgements and key sources of estimation uncertainty

In the application of the company’s accounting policies, the directors are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

 

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

3
Turnover and other revenue
2025
2024
£
£
Other revenue
Grant for promoting artisan development
35,000
35,000
Income from the advertising space provided in catalogues for Gifts for Life and Donations
151,106
155,914
New donors recruitment
15,960
11,080
Special pension refund
8,181
-
Voluntary income from retail and trade customers
-
37,330
Acquisition mailing recharges
53,519
37,628
Miscellaneous income
894
14,721
264,660
291,673
4
Interest receivable and similar income
2025
2024
£
£
Interest income
Interest on bank deposits
14,793
15,526
2025
2024
Investment income includes the following:
£
£
Interest on financial assets not measured at fair value through profit or loss
14,793
15,526
THE LEPROSY MISSION SHOP LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
- 20 -
5
Operating loss
2025
2024
Operating loss for the year is stated after charging:
£
£
Depreciation of owned tangible fixed assets
1,145
24
Amortisation of intangible assets
1,579
25,000
6
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2025
2024
Number
Number
Administration and marketing
8
8

Their aggregate remuneration comprised:

2025
2024
£
£
Wages and salaries
316,378
297,355
Social security costs
32,546
32,271
Pension costs
38,149
35,680
387,073
365,306
7
Directors' remuneration
2025
2024
£
£
Remuneration for qualifying services
71,047
68,618
Company pension contributions to defined contribution schemes
7,504
6,812
78,551
75,430
8
Auditor's remuneration
2025
2024
Fees payable to the company's auditor:
£
£
For audit services
Audit of the financial statements of the company
8,200
8,000
THE LEPROSY MISSION SHOP LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
- 21 -
9
Dividends and distributions
2025
2024
£
£
Distributions to parent charity under gift aid
Amounts paid
-
0
1,947
10
Intangible fixed assets
Website
£
Cost
At 1 January 2025
75,000
Additions
7,348
Disposals
(75,000)
At 31 December 2025
7,348
Amortisation and impairment
At 1 January 2025
75,000
Amortisation charged for the year
1,579
Disposals
(75,000)
At 31 December 2025
1,579
Carrying amount
At 31 December 2025
5,769
At 31 December 2024
-
0
11
Tangible fixed assets
Office and Computer Equipment
£
Cost
At 1 January 2025
34,360
Additions
3,165
Disposals
(8,950)
At 31 December 2025
28,575
Depreciation and impairment
At 1 January 2025
33,514
Depreciation charged in the year
1,145
Eliminated in respect of disposals
(8,950)
At 31 December 2025
25,709
THE LEPROSY MISSION SHOP LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
11
Tangible fixed assets
Office and Computer Equipment
£
(Continued)
- 22 -
Carrying amount
At 31 December 2025
2,866
At 31 December 2024
846
12
Stocks
2025
2024
£
£
Goods for resale
205,479
138,392
13
Debtors
2025
2024
Amounts falling due within one year:
£
£
Trade debtors
29,791
41,186
Amounts owed by group undertakings
3,068
-
0
Other debtors
257
-
0
Prepayments and accrued income
22,356
26,983
55,472
68,169
14
Creditors: amounts falling due within one year
2025
2024
£
£
Trade creditors
96,020
198,380
Amounts owed to group undertakings
-
0
101,979
Taxation and social security
46,950
47,802
Other creditors
96,162
79,693
Accruals and deferred income
14,466
16,997
253,598
444,851
THE LEPROSY MISSION SHOP LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
- 23 -
15
Retirement benefit schemes
2025
2024
Defined contribution schemes
£
£
Charge to profit or loss in respect of defined contribution schemes
33,799
29,880

A group personal pension scheme (GPP) has been set up with AVIVA (formerly Friends Life). The Leprosy Mission Shop Limited makes an employer's contribution of 10% of the monthly pensionable salary to AVIVA.

 

The assets of the scheme are held separately from those of the company in an independently administered fund.

 

The group personal pension Scheme (GPP) is a defined contributory pension arrangement set up by The Leprosy Mission as individual employee policy. When employees leave the organisation, they can move this policy to other employers and/or make their own contribution. This pension pot is invested in stocks and shares by the Insurance company and the member can draw their pension from the age of 55.

Defined benefit schemes

 

The company used to operate a non-contributory multi-employer pension scheme providing benefits based upon career-averaged re-valued earnings. The career averaged re-valued earnings scheme was closed to new members effective from 12 November 2007 and with effect from 31 March 2013 the scheme was closed to new accruals. The company's pension contributions are determined by a qualified actuary on the basis of triennial valuations.

 

The individual accounts of each of the participating employers need to reflect the obligation they have to the scheme. The scheme cannot identify each employer's share of the total scheme assets. Therefore, it is not possible to use defined benefit accounting for an individual company. Accordingly, the scheme is accounted for as if it is a defined contribution scheme.

 

The last actuarial valuation was made at 31 December 2021 using the projected unit valuation method and the market value of the assets represented 100% of the market value of the liabilities. After taking into account the results of the triennial valuation carried out as at 31 December 2021, the company agreed to make an annual contribution of £5,800 to cover the administrative expenses of the scheme. This amount is payable with effect from 1 January 2023 payable in equal monthly instalments for a period of three years, into the Special Pension Account held by The Leprosy Mission International.

 

FRS102 requires an entity that has entered into an agreement to reduce the historic deficit on a multi-employer pension scheme, to recognise the liability in accordance with FRS102 section 28.13 and 28.13A. The last valuation of the scheme was carried out with an effective date of 31 December 2021. This valuation revealed the Scheme was in surplus on the agreed Statutory Funding Objective basis agreed between the employers and the pension scheme trustees. As a result no recovery plan was required. Therefore the FRS102 liability as at 31 December 2025 is £nil (2024 - £nil).

 

On 30 April 2024 a buy-in transaction was agreed with Legal & General Assurance Society Limited securing the benefits of the whole membership of the Scheme.

 

On 13 February 2026 a Deed was signed to formally complete the wind-up of the Scheme. All assets and liabilities were transferred out of the Scheme within the period and a Deed of Termination was executed on 13 February 2026 and the Scheme was closed as of 13 February 2026.

THE LEPROSY MISSION SHOP LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
- 24 -
16
Share capital
2025
2024
2025
2024
Ordinary share capital
Number
Number
£
£
Issued and fully paid
Ordinary shares of £5 each
40,000
40,000
200,000
200,000
17
Related party transactions
Transactions with related parties

During the year the company received a loan of £nil (2024 - £100,000) from its parent, The Leprosy Mission International (TLMI). At 31 December 2025 an amount of £3,068 (2024 - £101,979 due to TLMI) was due from TLMI. TLMI also made a grant of £35,000 (2024 - £35,000) to promote development of artisan products by people affected by leprosy and disability groups. This is in support of TLMI's charitable objectives.

 

During the year the company purchased services from Stuart Green Research Limited, a company of which Stuart Green is a director, totalling £nil (2024 - £1,500).

18
Ultimate controlling party

The ultimate parent company is The Leprosy Mission International (TLMI), a company limited by guarantee and a registered charity. The company which is registered in England and Wales is number 3591514 and is registered charity number 1076356.

 

The Leprosy Mission International is both the smallest and largest group for which financial statements are prepared. The group financial statements are available to the public and may be obtained from Companies House.

19
Cash absorbed by operations
2025
2024
£
£
Loss after taxation
(43,336)
(12,714)
Adjustments for:
Investment income
(14,793)
(15,526)
Amortisation and impairment of intangible assets
1,579
25,000
Depreciation and impairment of tangible fixed assets
1,145
24
Movements in working capital:
(Increase)/decrease in stocks
(67,087)
10,089
Decrease/(increase) in debtors
12,697
(66,888)
(Decrease)/increase in creditors
(191,253)
22,344
Cash absorbed by operations
(301,048)
(37,671)
THE LEPROSY MISSION SHOP LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
- 25 -
20
Analysis of changes in net funds
1 January 2025
Cash flows
31 December 2025
£
£
£
Cash at bank and in hand
934,623
(296,768)
637,855
2025-12-312025-01-01falsefalsefalseCCH SoftwareCCH Accounts Production 2025.300Gordon Brown - Represents The Leprosy Mission Global Fellowship from 25 September 2025Gareth Evans - Appointed 16 December 2025Nicholas GreenStuart Green - ChairEsther KwanItayi Mapuranga - Resigned 1 July 2025Karen MitchellAmanda Norman - Chief Executive OfficerColin Osborne - Represented The Leprosy Mission Global Fellowship until 25 September 2025Peter Waddup - Represents the UK Supporting Countries of The Leprosy Mission030458642025-01-012025-12-3103045864bus:Director12025-01-012025-12-3103045864bus:Director22025-01-012025-12-3103045864bus:Director32025-01-012025-12-3103045864bus:Director42025-01-012025-12-3103045864bus:Director52025-01-012025-12-3103045864bus:Director72025-01-012025-12-3103045864bus:Director82025-01-012025-12-3103045864bus:Director92025-01-012025-12-3103045864bus:Director102025-01-012025-12-3103045864bus:Director62025-01-012025-12-3103045864bus:RegisteredOffice2025-01-012025-12-3103045864bus:Agent12025-01-012025-12-31030458642025-12-31030458642024-01-012024-12-3103045864core:RetainedEarningsAccumulatedLosses2024-01-012024-12-3103045864core:RetainedEarningsAccumulatedLosses2025-01-012025-12-3103045864core:IntangibleAssetsOtherThanGoodwill2025-12-3103045864core:IntangibleAssetsOtherThanGoodwill2024-12-3103045864core:Non-standardIntangibleAssetClass1ComponentIntangibleAssetsOtherThanGoodwill2025-12-3103045864core:Non-standardIntangibleAssetClass1ComponentIntangibleAssetsOtherThanGoodwill2024-12-31030458642024-12-3103045864core:PlantMachinery2025-12-3103045864core:PlantMachinery2024-12-3103045864core:WithinOneYear2025-12-3103045864core:WithinOneYear2024-12-3103045864core:CurrentFinancialInstruments2025-12-3103045864core:CurrentFinancialInstruments2024-12-3103045864core:ShareCapital2025-12-3103045864core:ShareCapital2024-12-3103045864core:RetainedEarningsAccumulatedLosses2025-12-3103045864core:RetainedEarningsAccumulatedLosses2024-12-3103045864core:ShareCapital2023-12-3103045864core:RetainedEarningsAccumulatedLosses2023-12-3103045864core:ShareCapitalOrdinaryShareClass12025-12-3103045864core:ShareCapitalOrdinaryShareClass12024-12-31030458642024-12-31030458642023-12-3103045864core:IntangibleAssetsOtherThanGoodwill2025-01-012025-12-3103045864core:Non-standardIntangibleAssetClass1ComponentIntangibleAssetsOtherThanGoodwill2025-01-012025-12-3103045864core:PlantMachinery2025-01-012025-12-3103045864core:Non-standardIntangibleAssetClass1ComponentIntangibleAssetsOtherThanGoodwill2024-12-3103045864core:Non-standardIntangibleAssetClass1ComponentIntangibleAssetsOtherThanGoodwillcore:ExternallyAcquiredIntangibleAssets2025-01-012025-12-3103045864core:PlantMachinery2024-12-3103045864bus:OrdinaryShareClass12025-01-012025-12-3103045864bus:OrdinaryShareClass12025-12-3103045864bus:OrdinaryShareClass12024-12-3103045864bus:PrivateLimitedCompanyLtd2025-01-012025-12-3103045864bus:FRS1022025-01-012025-12-3103045864bus:Audited2025-01-012025-12-3103045864bus:FullAccounts2025-01-012025-12-31xbrli:purexbrli:sharesiso4217:GBP